Natera
Natera, Inc. is a genetic testing and diagnostics company that specializes in developing non-invasive tests for prenatal screening, cancer detection, and organ transplant rejection. The company generates revenue by providing these cutting-edge diagnostic services to healthcare providers, laboratories, and patients, leveraging its innovative technology to deliver accurate and timely results.
The ten most recent trades of Natera in the ARKK ETF.View all trades
Date | Direction | Market Value | % of Position | % of ETF |
---|---|---|---|---|
Dec 31, 2024 | Buy | $9,803,614 | 14.81% | 0.15% |
Oct 30, 2024 | Buy | $7,902,466 | 17.80% | 0.14% |
Oct 29, 2024 | Buy | $1,020,372 | 2.40% | 0.02% |
Aug 13, 2024 | Buy | $528,987 | 1.32% | 0.01% |
Aug 12, 2024 | Buy | $1,237,714 | 3.26% | 0.02% |
Aug 09, 2024 | Buy | $3,235,504 | 9.68% | 0.06% |
Jul 01, 2024 | Buy | $3,060,428 | 10.33% | 0.05% |
May 30, 2024 | Buy | $500,301 | 2.04% | 0.01% |
May 29, 2024 | Buy | $1,573,408 | 6.98% | 0.03% |
May 28, 2024 | Buy | $3,491,537 | 18.48% | 0.06% |